Routine screening for coagulation inhibitors prior to prescribing the pill: Prevalence data from a large cohort of German pill starters

European Journal of Contraception and Reproductive Health Care

Volumn 1, Issue 1, 1996, Pages 47-52

  Winkler, U H ^a   Zierleyn, J P ^a   Schulte, H ^a   Collet, W ^b   Schindler, A E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Winicker Norimed GmbH   (Germany)

Author keywords

Antithrombin III; Coagulation inhibitors; Oral contraceptives; Protein C; Protein S; Routine screening

Indexed keywords

ANTITHROMBIN III; ORAL CONTRACEPTIVE AGENT; PROTEIN C;

ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLOOD; FEASIBILITY STUDY; FEMALE; GERMANY; HUMAN; LABORATORY DIAGNOSIS; MASS SCREENING; METABOLISM; METHODOLOGY; PRESCRIPTION; PREVALENCE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR; STANDARD;

ADULT; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; CONTRACEPTIVES, ORAL; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FEMALE; GERMANY; HUMANS; MASS SCREENING; PRESCRIPTIONS, DRUG; PREVALENCE; PROTEIN C; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTORS;

EID: 0030089095     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189609150655     Document Type: Article

References (23)

1. Royal College of Obstetricians and Gynaecologists. Guidelines for prescribing combined oral contraceptives. Br Med J 1996; 312: 121-2
2. Winkler UH, Bühler K, Oberhoff C, et al. The dynamic balance of hemostasis: a key for understanding thromboembolism in oral contraceptive users. In Genazzani AR, ed. Current Research in Gynecology and Obstetrics. Carnforth, UK: Parthenon Publishing, 1991; 389-94
3. Pabinger I, Schneider B, the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S deficiency taking oral contraceptives. Thromb Haemost 1994; 71: 548-52
4. De Stefano G, Leone S, Mastragelo A, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 71: 799-800
5. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7
6. Melis GB, Fruzzetti, Paoletti AM, et al. Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment. Contraception 1984; 30: 575-83
7. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042-8
8. Winkler UH, Koslowski S, Oberhoff C, et al. Changes of the dynamic equilibrium of hemostatis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 μg ethinylestradiol. Adv Contracept 1991; 7: 273-84
9. Winkler UH. Stellungnahme zum Bescheid des Bundesgesundheitsamtes vom 7.12.92 zur Änderung der Packungsbeilage bei oralen Kontrazeptiva. Frauenarzt 1993; 34: 234-4
10. Winkler UH, Hölscher T, Schulte H, et al. 20 μg versus 30 μg ethinylestradiol combined with 150 μg desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol 1996; in press
11. Jespersen J, Bertina RM, Haverkate F, eds. ECAT Assay Procedures: a Manual of Laboratory Techniques. Dordrecht: Kluwer Academic Publishers, 1992
12. Gladson CL, Scharrer I, Hach V, et al. The frequency of type-I heterozygous protein S and protein C deficiency in 141 unrelated patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22
13. Heijboer H, Brandjes DPM, Büller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-15
14. Vikydal R, Kominger C, Kyrle PA, et al. The prevalence of hereditary antithrombin III deficiency in patients with a history of venous thromboembolism. Thromb Haemost 1985; 54: 744-5
15. Trauchst-Van Horn JJ, Capeless EL, Easterling TR, et al. Pregnancy loss and thrombosis with protein C deficiency. Am J Obstet Gynecol 1992; 167: 9968-72
16. Bertina RM, Reitsma PH, Rosendaal FR, et al. Resistance to activated protein C and factor V Leiden as risk Factors for venous thrombosis. Thromb Haemostas 1995; 74: 449-53
17. Harpel PC. Blood proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. New York: Lippincott, 1987: 219-34
18. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency: incidence and clinical features. Am J Med 1989; 87: 34-38S
19. Miletich J, Broze GJ. Age and gender dependence of total protein S antigen in the normal adult population. Blood 1988; 72: 371a
20. Comp P, Doray D, Patton D, et al. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67; 504-8
21. Bauer KA. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-8
22. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinology 1992; 6: 3-10
23. Briet E, Meer FJM van der, Rosendaal FR, et al. The family history and inherited thrombophilia. Br J Haematol 1994; 87: 348-52